Bone Biologics Co. (NASDAQ:BBLG) Sees Significant Growth in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 28,700 shares, an increase of 129.6% from the August 31st total of 12,500 shares. Based on an average daily trading volume, of 4,820,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 5.5% of the company’s stock are sold short.

Bone Biologics Price Performance

NASDAQ:BBLG opened at $2.35 on Friday. The firm has a 50-day moving average of $1.66 and a two-hundred day moving average of $1.67. Bone Biologics has a 1-year low of $0.80 and a 1-year high of $10.56.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($1.39) by $0.72. On average, research analysts expect that Bone Biologics will post -3.17 EPS for the current year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.